Evidence map›Paper›PMID 42321881›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2026

Triggers, clinical spectra and outcomes of pediatric anaphylaxis in a tertiary center: impact of comorbidities and cofactors on severity.

Necmiye Keser-Ozturk, Yasir Maghdeed, Selcen Bozkurt, Melek Yorgun-Altunbas, Salim Can, Razin Amirov, Ramin Mahmudov, Burkay Cagan Colak, Emel Eksi-Alp, Sevgi Bilgic-Eltan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Necmiye Keser-OzturkDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Yasir MaghdeedDepartment of Pediatrics, Faculty of Medicine, Marmara University, Istanbul, Turkey.
Selcen BozkurtDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Melek Yorgun-AltunbasDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Salim CanDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Razin AmirovDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Ramin MahmudovDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Burkay Cagan ColakDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Emel Eksi-AlpDivision of Pediatric Emergency Medicine, Department of Pediatrics, Faculty of Medicine, Marmara University, Istanbul, Turkey.
Sevgi Bilgic-EltanDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Ahmet OzenDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Safa BarisDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey.
Elif Karakoc-AydinerDivision of Allergy and Immunology, Department of Pediatrics, Istanbul Jeffrey Model Diagnostic and Research Center for Primary Immunodeficiencies, The Isil Berat Barlan Center for Translational Medicine, Immune Deficiency Research and Application Center, Faculty of Medicine, Marmara University, European Academy of Allergy and Clinical Immunology Marmara University Hospital Center of Excellence, Istanbul, Turkey. elifaydiner@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnaphylaxis is a potentially life-threatening systemic hypersensitivity reaction. While triggers, clinical manifestations, and severity are influenced by age and sociocultural factors, most evidence regarding the impact of comorbidities and cofactors comes from adult studies. This study aimed to characterize the triggers, clinical features, and outcomes of pediatric anaphylaxis in a tertiary care center, with a particular emphasis on risk factors for severity.

methodsWe retrospectively reviewed records from August 2023-August 2024 at the European Allergy Academy and Clinical Immunology Center of Excellence in Istanbul. Children aged 0-18 years (n = 100) with anaphylaxis as defined by the 2020 World Allergy Organization (WAO) criteria were included. Demographic, clinical, and follow-up data were collected. The updated 2024 (WAO) grading system was used to classify severity.

resultsOf the 3,959 records, 100 children fulfilled the inclusion criteria. A female predominance was noted in those ≤ 4 years, with males predominating thereafter. Medications were the leading trigger, followed by food, venom, and idiopathic causes. Foods were more prevalent among outpatients, and drugs were more prevalent among inpatients. Comorbidities were more common in hospital-onset anaphylaxis. Atopy was more common in food-induced anaphylaxis, whereas infections and polypharmacy were more common in drug-induced cases. Food-related reactions with endogenous factors were typically milder, whereas drug-related reactions-especially in older patients with polypharmacy or hospital-onset-tended to be more severe. Biphasic reactions were associated with delayed presentation, elevated WBC/ANC, and older age. Intramuscular adrenaline was administered in 95% of the patients, but prehospital autoinjector use was rare.

conclusionOur findings underscore the need for early recognition and management, systematic evaluation of contributing factors, risk-adapted monitoring, and individualized follow-up in pediatric anaphylaxis patients.

Indexed as

Biphasic reactionsCofactorsComorbiditiesPediatric anaphylaxisRisk factorsSeverityTriggers

Identifiers

PMID42321881
PMCPMC13531739

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.